96 reports

  • Table of Contents
  • List of Figures & Tables

Global Allergy Immunotherapy Market: Industry Analysis & Outlook (2019- 2023) ##.

  • Allergy Drug
  • Allergy Immunotherapy
  • Immunotherapy
  • Merck & Co., Inc.
  • Stallergenes Greer plc

A prime example of this is the emergence of immunotherapies and PD-##/ PD-L## targeted agents.

  • Cancer
  • Chemotherapy
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.
  • Market segmentation by type of immunotherapy
  • NON-SPECIFIC IMMUNOTHERAPIES

Examples of immunotherapy drugs that target PD- ## include nivolumab (Opdivo) and pembrolizumab (Keytruda).

  • Cancer
  • Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Hoffmann-La Roche Sales by Region; 2018 ## ##.

  • Immunotherapy
  • Oncology
  • Therapy
  • World
  • Merck & Co., Inc.
  • Market segmentation by type of immunotherapy
  • NON-SPECIFIC IMMUNOTHERAPIES

Examples of immunotherapy drugs that target PD- ## include nivolumab (Opdivo) and pembrolizumab (Keytruda).

  • Cancer
  • Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.
  • CRC THERAPEUTICS MARKET, GLOBAL, ALL PIPELINE PRODUCTS, PHASE I, 2018

Nivolumab as Programmed Death-## (PD-##) Inhibitor for Targeted Immunotherapy in Tumor.

  • Chemotherapy
  • Colorectal Cancer
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.
  • 8.3 IMMUNOTHERAPIES
  • PROVIDES A SWOT ANALYSIS FOR MERCK KGAA.

US KEY OPINION LEADER CURRENTLY, THERE IS ONLY ONE LATE-STAGE IMMUNOTHERAPY IN THE PIPELINE THAT TARGETS MSS PATIENTS, ROCHE' S TECENTRIQ.

  • Colorectal Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

N. (2016) ' UPDATE ON PSORIASIS IMMUNOPATHOGENESIS AND TARGETED IMMUNOTHERAPY', SEMINARS IN IMMUNOPATHOLOGY, PP. ##-##.

  • Dermatological Condition
  • Immunotherapy
  • Therapy
  • World
  • Merck & Co., Inc.

Topical immunotherapies are another treatment option for extensive alopecia.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Immunotherapy
  • Merck & Co., Inc.
  • 9.6 PROMISING DRUGS IN EARLY-STAGE DEVELOPMENT
  • LEADING TREATMENTS FOR MELANOMA, 2016

JOURNAL OF IMMUNOTHERAPY; ##(##): ##-##.

  • Hospital
  • Immunotherapy
  • Therapy
  • Oceania
  • Merck & Co., Inc.

THESE INCLUDE IMMUNOTHERAPIES, ANTIBODY-DRUG CONJUGATES (ADCS), BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES (ABS) AND MONOCLONAL ABS (MABS).

  • Immunotherapy
  • Protein Therapy
  • Vaccine
  • Market Size
  • Merck & Co., Inc.
  • CANCER VACCINES MARKET, GLOBAL, MARKET SIZE ($BN)
  • Untitled

Phase II Phase II Cellular Immunotherapy to Inhibit NY ESO-## for Oncology Kite Pharma, Inc.

  • Cancer Immunotherapy
  • Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.
  • GLOBAL NON-SPECIFIC IMMUNOTHERAPIES MARKET
  • AMGEN

In May 2015, the company and Merck expanded their collaboration to evaluate the efficacy and safety of T-VAC (its investigational oncolytic immunotherapy) in combination with Keytruda (Merck' s anti-PD-## therapy), in Phase ##, open-label trial of people with recurrent o

  • Cancer Immunotherapy
  • Immunotherapy
  • Therapy
  • United States
  • Merck & Co., Inc.

THESE INCLUDE IMMUNOTHERAPIES, ANTIBODY-DRUG CONJUGATES (ADCS), BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES (ABS) AND MONOCLONAL ABS (MABS).

  • Immunotherapy
  • Monoclonal Antibody
  • Vaccine
  • Market Size
  • Merck & Co., Inc.
  • c. Patent Cliff
  • V. Advanced/Stage IV/Metastatic RCC

Combination of approved immunotherapies with new in-research immunotherapies has resulted in improved response rates for patients with RCC.

  • Cancer
  • Immunotherapy
  • Renal Cancer
  • Therapy
  • Merck & Co., Inc.

PLoS One; ##(##): e## Lee P, et al. (2012).

  • Immunotherapy
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Merck & Co., Inc.
  • ONCOLOGY, GLOBAL, LICENSING DEALS BY MOLECULE TYPE AND MECHANISM OF ACTION, 2006-2017
  • human cancers

Novartis AG Karolinska Institutet Phase I RG-## HKT-## Phase I Phase I Phase I Cellular Immunotherapy to Target NY-ESO- ## for Metastatic Melanoma Cellular Immunotherapy to Target NY-ESO- ## for Oncology Shenzhen Second People' s Hospital Phase I Cellular

  • Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • Merck & Co., Inc.
  • hydroxychloroquine + sorafenib tosylate

Subjects were randomized in a ##:##:## ratio to receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Breast Cancer
  • Immunotherapy
  • Therapy
  • Forecast
  • Merck & Co., Inc.

In melanoma models, HSP## inhibition by ganetespib increased the expression levels of interferon response genes, notably interferon-induced protein with tetratricopeptide repeats ## (IFIT##), IFIT##, and IFIT##, which was found to further enhance the T-cell-mediated killing of melanoma cells an

  • Immunotherapy
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Immunotherapy
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Merck & Co., Inc.
  • IMMUNOTHERAPY DRUGS MARKET, BY REGION
  • IMMUNOTHERAPY DRUGS MARKET, BY TYPE OF DRUG

(Switzerland). ## ##. ##. ## U.

  • Cancer
  • Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.
  • 10.3 ADVAXIS

At the 2012 Society for Immunotherapy Annual Meeting, results from a Phase ## study of CDX-## were presented.

  • Cancer Immunotherapy
  • Immunotherapy
  • Therapy
  • Vaccine
  • Merck & Co., Inc.

Cellular immunotherapies had two deals, while antisense RNAi oligonucleotides and antibodies had one deal each.

  • Immunotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

Kevzara was developed using Regeneron' s VelocImmune antibody technology by Regeneron and Sanofi in a collaboration that started in 2007.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Market Size
  • Merck & Co., Inc.

Immunotherapies account for only nine therapy products.

  • Clinical Trial
  • Dementia
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.
  • CANCER IMMUNOTHERAPIES MARKET, GLOBAL, CO-DEVELOPMENT DEALS VALUED ABOVE $100M, 2006-2016
  • B) Phase I

Immunotherapy in ovarian cancer - where are we going?

  • Cancer Immunotherapy
  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Merck & Co., Inc.

Efficacy and safety of emerging immunotherapies in psoriasis.

  • Autoimmune Disease
  • Immunology
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.

Journal for ImmunoTherapy of Cancer; ##(##): ##-## Kim S, et al. (2005).

  • Gastric Cancer
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.
  • Roche Group
  • IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
  • Date

ADDITIONALLY, THE ROLE OF IMMUNOTHERAPY AS A VIABLE OPTION FOR THE TREATMENT OF SEVERAL OTHER DISEASES WORLDWIDE IS INCREASING. ##. ##. ##. ## Mutual agreements among companies from drug ##. ##. ##. ## Increasing Importance of CART Therapies IMMUNOTHERAPY HAS EMERGED AS ONE OF THE PROMI

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Merck & Co., Inc.

From tool to therapy: a timeline of monoclonal antibody technology.

  • Immunotherapy
  • Medical Biotechnology
  • Monoclonal Antibody
  • AbbVie Inc.
  • Merck & Co., Inc.